XML 168 R111.htm IDEA: XBRL DOCUMENT v3.25.0.1
Goodwill and other intangible assets - Schedule of Movements in Other Intangible Assets (Details)
€ in Millions, $ in Millions
 12 Months Ended
Dec. 31, 2024
EUR (€)
Dec. 31, 2023
EUR (€)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
EUR (€)
Disclosure of detailed information about intangible assets [line items]        
Other intangible assets, beginning balance € 24,319 € 21,640    
Amortization expense(e) (1,749) (1,911) [1]   € (1,804) [1]
Other intangible assets, ending balance 22,629 24,319   21,640
Gross value        
Disclosure of detailed information about intangible assets [line items]        
Other intangible assets, beginning balance 85,313 81,716   78,865 [2]
Changes in scope of consolidation [3] 1,745 3,401   464
Acquisitions and other increases 1,554 [4] 3,112 [4]   571
Disposals and other decreases (1,514) (683)   (543)
Currency translation differences 3,331 (1,837)   2,533
Transfers [5] 3 (396)   (174)
Increase (decrease) through reclassification, intangible assets other than goodwill [2] (9,366)      
Other intangible assets, ending balance 81,066 85,313   81,716
Accumulated amortization & impairment        
Disclosure of detailed information about intangible assets [line items]        
Other intangible assets, beginning balance (60,994) (60,076)   (57,458) [2]
Changes in scope of consolidation   33 [3]   11
Amortization expense(e) (2,200) (2,345)   (2,196) [6]
Impairment losses, net of reversals [7] (264) (932)   454
Disposals and other decreases 722 629   525
Currency translation differences (2,134) 1,287   (1,591)
Transfers [5] (5) 410   179
Increase (decrease) through reclassification, intangible assets other than goodwill [2] 6,438      
Other intangible assets, ending balance (58,437) (60,994)   (60,076)
Acquired R&D        
Disclosure of detailed information about intangible assets [line items]        
Other intangible assets, beginning balance 6,038 6,226    
Other intangible assets, ending balance 8,369 6,038   6,226
Acquired R&D | Gross value        
Disclosure of detailed information about intangible assets [line items]        
Other intangible assets, beginning balance 9,772 10,354   11,207 [2]
Changes in scope of consolidation [3] 1,745 113   0
Acquisitions and other increases 1,006 [4] 1,062 [4]   277
Disposals and other decreases (58) (262)   (72)
Currency translation differences 606 (242)   518
Transfers [5] (52) (1,253)   (1,576)
Increase (decrease) through reclassification, intangible assets other than goodwill [2] (153)      
Other intangible assets, ending balance 12,866 9,772   10,354
Acquired R&D | Accumulated amortization & impairment        
Disclosure of detailed information about intangible assets [line items]        
Other intangible assets, beginning balance (3,734) (4,128)   (3,477) [2]
Changes in scope of consolidation   0 [3]   0
Amortization expense(e) 0 0   0 [6]
Impairment losses, net of reversals [7] (638) (90)   (1,107)
Disposals and other decreases 58 262   75
Currency translation differences (191) 94   (7)
Transfers [5] (2) 128   388
Increase (decrease) through reclassification, intangible assets other than goodwill [2] 10      
Other intangible assets, ending balance (4,497) (3,734)   (4,128)
Products, trademarks and other rights        
Disclosure of detailed information about intangible assets [line items]        
Other intangible assets, beginning balance 17,825 14,927    
Other intangible assets, ending balance 13,841 17,825   14,927
Products, trademarks and other rights | Gross value        
Disclosure of detailed information about intangible assets [line items]        
Other intangible assets, beginning balance 73,733 69,579   65,906 [2]
Changes in scope of consolidation [3] 0 3,287   499
Acquisitions and other increases 444 [4] 1,970 [4]   195
Disposals and other decreases (1,447) (380)   (423)
Currency translation differences 2,708 (1,584)   1,994
Transfers [5] 66 861   1,408
Increase (decrease) through reclassification, intangible assets other than goodwill [2] (9,156)      
Other intangible assets, ending balance 66,348 73,733   69,579
Products, trademarks and other rights | Gross value | Antibodies Collaboration agreement | Teva Pharmaceuticals        
Disclosure of detailed information about intangible assets [line items]        
Acquisitions and other increases | $     $ 500  
Products, trademarks and other rights | Gross value | Antibodies Collaboration agreement | Janssen Pharmaceuticals, Inc        
Disclosure of detailed information about intangible assets [line items]        
Acquisitions and other increases | $     $ 175  
Products, trademarks and other rights | Accumulated amortization & impairment        
Disclosure of detailed information about intangible assets [line items]        
Other intangible assets, beginning balance (55,908) (54,652)   (52,744) [2]
Changes in scope of consolidation   33 [3]   0
Amortization expense(e) (2,094) (2,225)   (2,099) [6]
Impairment losses, net of reversals [7] 373 (842)   1,561
Disposals and other decreases 655 326   411
Currency translation differences (1,928) 1,184   (1,567)
Transfers [5] (3) 268   (214)
Increase (decrease) through reclassification, intangible assets other than goodwill [2] 6,398      
Other intangible assets, ending balance (52,507) (55,908)   (54,652)
Products, trademarks and other rights | Accumulated amortization & impairment | IO License and Collaboration agreement        
Disclosure of detailed information about intangible assets [line items]        
Amortization expense(e)       (226)
Software        
Disclosure of detailed information about intangible assets [line items]        
Other intangible assets, beginning balance 456 487    
Other intangible assets, ending balance 419 456   487
Software | Gross value        
Disclosure of detailed information about intangible assets [line items]        
Other intangible assets, beginning balance 1,808 1,783   1,752 [2]
Changes in scope of consolidation [3] 0 1   (35)
Acquisitions and other increases 104 [4] 80 [4]   99
Disposals and other decreases (9) (41)   (48)
Currency translation differences 17 (11)   21
Transfers [5] (11) (4)   (6)
Increase (decrease) through reclassification, intangible assets other than goodwill [2] (57)      
Other intangible assets, ending balance 1,852 1,808   1,783
Software | Accumulated amortization & impairment        
Disclosure of detailed information about intangible assets [line items]        
Other intangible assets, beginning balance (1,352) (1,296)   (1,237) [2]
Changes in scope of consolidation   0 [3]   11
Amortization expense(e) (106) (120)   (97) [6]
Impairment losses, net of reversals [7] 1 0   0
Disposals and other decreases 9 41   39
Currency translation differences (15) 9   (17)
Transfers [5] 0 14   5
Increase (decrease) through reclassification, intangible assets other than goodwill [2] 30      
Other intangible assets, ending balance € (1,433) € (1,352)   € (1,296)
[1] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation
[2] (a)Comprises the other intangible assets of Opella, now reclassified to Assets held for sale at December 31, 2024 in accordance with IFRS 5 (see note D.1.).
[3] (c)The “Changes in scope of consolidation” line mainly comprises the fair value of intangible assets recognized in connection with acquisitions made during the period (see Note D.1.)
[4] (f)This line mainly comprises:
In 2023:
–the rights acquired as a result of the simplification agreed between Sanofi and AstraZeneca in April 2023 in respect of the agreements on Beyfortus
(nirsevimab) (see Note C.2.);
–an upfront payment of $500 million relating to the rights acquired under the agreement with Teva Pharmaceuticals on the co-development and co-
commercialization of TEV’574;and
–an upfront payment of $175 million for the rights acquired under the agreement with Janssen Pharmaceuticals, Inc. relating to a vaccine against
extra-intestinal pathogenic strains of E-Coli.
In 2024:
–an upfront payment of $500 million for the rights acquired under the agreement with Novavax relating to the co-exclusive license agreement for the
co-commercialization of a COVID-19 vaccine and the development of a combined flu-COVID-19 vaccine; and
–an upfront payment of $300 million for the rights acquired under an agreement with Corxel Pharmaceuticals for the development and
commercialization rights to aficamten in China.
[5] (b)The “Transfers” line mainly comprises (i) acquired R&D that came into commercial use during the period and (ii) reclassifications of assets (other than
Opella assets) as Assets held for sale.
[6] (e)The amendment to the terms of the IO License and Collaboration Agreement resulted in the recognition of an amortization charge of €226 million in 2022 (see Note C.1.)
[7] (d)See Note D.5.